Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.71 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365726 | 1.00 | HTR2A (1.00) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL2244831 | 0.86 | HTR2A (1.00) | HTR2AHRH1HTR2CRETSLC6A2 | |
| Hydrochloric Acid SCHEMBL9084155 | 0.84 | HTR2A (0.96) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL11879547 | 0.83 | HTR2A (0.84) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL6997509 | 0.80 | HTR2A (0.66) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL11678484 | 0.79 | HTR2A (0.66) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL2941714 | 0.78 | HTR2A (0.62) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL9632433 | 0.77 | HTR2A (0.63) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL21996453 | 0.77 | HTR2A (0.61) | HTR2AHRH1HTR2CRETSLC6A2 | |
| SCHEMBL22049110 | 0.77 | HTR2A (0.61) | HTR2AHRH1HTR2CRETSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | claimed |
| US-20200352950-A1 | Novel method of treating dystonia | NEUROTOBE PHARMACEUTICALS INC. (KR) | 2020-11-12 | — | — | US | claimed |
| EP-3718549-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DYSTONIA | Korea Advanced Institute of Science and Technology (KR) | 2020-10-07 | — | — | EP | claimed |
| CN-111655265-A | Novel pharmaceutical composition for the treatment of dystonia | 韩国科学技术院 | 2020-09-11 | — | — | CN | claimed |
| US-20180318298-A1 | Method of Treating Obesity | MCMASTER UNIVERSITY (CA) | 2018-11-08 | — | — | US | claimed |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260125345-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | TERRAN BIOSCIENCES INC. | 2026-05-07 | — | — | US | disclosed |
| WO-2014018563-A2 | METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-1069132-B1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-10-01 | — | — | EP | disclosed |
| US-6277851-B1 | ORALLY ADMINISTERED TRYPSIN-RELATED SERINE PROTEASE INHIBITORS; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-08-21 | — | — | US | disclosed |
| EP-1069132-A1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318298-A1 | Method of Treating Obesity | GPR119, HTR2A, GIPR | HTR2A 2/4885HRH1 685/4885HTR2C 20/4885 |
| US-11278549-B2 | Method of treating obesity | GPR119, HTR2A, GIPR | HTR2A 2/4885HRH1 685/4885HTR2C 20/4885 |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | HTR2A 14/4885HRH1 402/4885HTR2C 2/4885 |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TPH2, TPH1, HTR1D | HTR2A 5/4885HRH1 1240/4885HTR2C 4/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2A 37/4885HRH1 1408/4885HTR2C 5/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR2A 2/4885HRH1 575/4885HTR2C 5/4885 |
| US-20260125345-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | HTR1D, GRIN2D, SLC1A2 | HTR2A 38/4885HRH1 3607/4885HTR2C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.